Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PA5108 Latanoprost FA SR Ocular Implant
- Development stage
- Phase 2
- Lead developer
- PolyActiva
- Modality
- Small Molecules, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Ophthalmic, Intraocular
01
Overview
PA5108 is a biodegradable ocular implant designed to deliver sustained release of latanoprost free acid (FA) for approximately 26 weeks. The implant utilizes PolyActiva's proprietary Prezia™ Sustained Drug Delivery Technology to release a constant daily dose of latanoprost with zero-order kinetics. It is delivered to the anterior segment through a delivery device, where the polymer rod falls into the angle of the eye. Unlike other ocular implants, PA5108 completely dissolves after drug delivery, leaving no residue behind, which allows for repeat dosing. This addresses the challenge of poor patient adherence with traditional eye drop therapy for glaucoma treatment.
- Other names
- PA5108 Ocular ImplantPA-5108 Ocular ImplantPA 5108 Ocular ImplantPA5108 Latanoprost FA SR Ocular ImplantPA-5108 Latanoprost FA SR Ocular ImplantPA 5108 Latanoprost FA SR Ocular ImplantPA5108 glaucoma implantPA-5108 glaucoma implantPA 5108 glaucoma implant
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on PA5108 Latanoprost FA SR Ocular Implant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PA5108 Latanoprost FA SR Ocular Implant.